Johnson & Johnson's INLEXZO Plus Cetrelimab Delivers Strong Pre-Surgical Results In Patients With Muscle Invasive Bladder Cancer Scheduled For Radical Cystectomy; Phase 2b SunRISe-4 study Shows 38% Of Patients Treated With INLEXZO-Based Combination Had No Detectable Cancer In The Bladder Prior To Surgery; Data Support Potential Role Of INLEXZO In Treating Muscle Invasive Bladder Cancer

Author: Benzinga Newsdesk | October 20, 2025 08:09am

https://www.jnj.com/media-center/press-releases/johnson-johnsons-inlexzo-gemcitabine-intravesical-system-plus-cetrelimab-delivers-strong-pre-surgical-results-in-patients-with-muscle-invasive-bladder-cancer-scheduled-for-radical-cystectomy

Johnson & Johnson (NYSE:JNJ) announced today that new data from the primary analysis of the ongoing Phase 2b SunRISe-4 study demonstrated that treatment with INLEXZO™ (gemcitabine intravesical system) plus intravenous (IV) cetrelimab (CET) before radical cystectomy resulted in a clinically meaningful rate of pathologic complete response (pCR) and pathologic overall response (pOR) in patients with muscle invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant platinum-based chemotherapy and are scheduled for bladder removal.[i] These data were featured as a late-breaking oral presentation at the European Society of Medical Oncology (ESMO) 2025 Congress (Abstract #LBA112).

Posted In: JNJ